Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRO051 open-label phase I/II dose-escalation study in Duchenne muscular dystrophy
NL-OMON21367Phase 2Recruiting
- Sponsor
- Prosensa
- Start
- Apr 2008
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of drisapersen in Duchenne muscular dystrophy (DMD) (4 arms), sponsored by Prosensa. Primary endpoints: Effect of PRO051 on dystrophin expression in muscle, Effect of PRO051 on muscle strength and function and 2 more. Started Apr 2008; status: recruiting.
02
Drugs
drisapersen
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NL-OMON21367.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON21367.